Chi Sheng Pharma & Biotech Co., Ltd. AI Stock Analysis
Chi Sheng Pharma & Biotech Co., Ltd. (4111) AI Stock Analysis
Chi Sheng Pharma & Biotech Co., Ltd.
(TPEx:4111)
Chi Sheng Pharma & Biotech scores well primarily on financial strength: record revenue and profits, expanding margins, an essentially debt-free balance sheet, and a strong rebound in operating and free cash flow that gives management flexibility to fund growth and dividends internally. Valuation reinforces the case, with a modest 9x P/E and a 4.6% dividend yield. The main drags are technical: the stock sits below all key moving averages with negative MACD and weak RSI/Stochastic readings, pointing to near-term softness. Historical volatility in earnings and free cash flow during capex-heavy years, plus only moderate returns on equity, keep the score from rising further.
Chi Sheng Pharma & Biotech Co., Ltd. (4111) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.70B
- Dividend Yield
- 4.56%
- Average Volume (3M)
- 64.60K
- Price to Earnings (P/E)
- 9.2
- Beta (1Y)
- 0.15
- Revenue Growth
- 5.33%
- EPS Growth
- 13.75%
- Country
- TW
- Employees
- 80
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Chi Sheng Pharma & Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company speci...
Chi Sheng Pharma & Biotech Co., Ltd. Financial Statement Overview
Summary
A strong financial profile anchored by a near debt-free balance sheet (debt-to-equity of 0.04, equity funding ~71% of assets) and a sharp rebound in cash generation, with operating cash flow nearly doubling to NT$409 million and free cash flow more than doubling to NT$315 million. The latest year was a record, with revenue up ~18% to NT$1.38 billion, net income up ~50% to NT$164 million, and margins expanding at the gross, operating and net levels. Offsetting this are a choppy multi-year track record — revenue declines in 2020 and 2023, negative free cash flow in 2021 and 2023 during heavy capex years — and only moderate returns on equity of 11.9%.
Income Statement
78PositiveBalance Sheet
88Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.42B | 1.38B | 1.17B | 1.06B | 1.14B | 1.02B |
| Gross Profit | 533.27M | 507.61M | 397.18M | 343.10M | 422.51M | 356.58M |
| EBITDA | 287.29M | 271.75M | 204.56M | 150.75M | 236.69M | 211.94M |
| Net Income | 189.06M | 164.28M | 110.63M | 68.67M | 154.01M | 80.75M |
Balance Sheet | ||||||
| Total Assets | 2.04B | 1.94B | 1.75B | 1.77B | 1.80B | 1.66B |
| Cash, Cash Equivalents and Short-Term Investments | 472.29M | 443.91M | 336.19M | 381.05M | 456.25M | 252.27M |
| Total Debt | 44.98M | 48.77M | 185.94M | 122.90M | 290.38M | 292.20M |
| Total Liabilities | 634.64M | 557.04M | 475.08M | 547.04M | 578.38M | 559.04M |
| Stockholders Equity | 1.40B | 1.38B | 1.27B | 1.22B | 1.22B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | 220.81M | 315.19M | 127.98M | -26.98M | 109.00M | -126.18M |
| Operating Cash Flow | 307.65M | 409.05M | 213.20M | 74.52M | 214.86M | 139.33M |
| Investing Cash Flow | -88.41M | -97.17M | -86.31M | -76.61M | 63.24M | -289.02M |
| Financing Cash Flow | -69.79M | -204.17M | -171.75M | -73.11M | -74.88M | 66.68M |
Chi Sheng Pharma & Biotech Co., Ltd. Peers Comparison
Overall Rating
- TW:411176Outperform
TW:415369Neutral
TW:129467Neutral
TW:655847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4111 | 76Outperform | TWD 1.71B | 9.16 | ― | 4.56% | 5.33% | 13.75% |
| TW:4153 | 69Neutral | TWD 1.74B | 16.13 | ― | 6.39% | 9.73% | 36.89% |
| TW:1294 | 67Neutral | TWD 1.62B | 10.44 | ― | 6.73% | 20.43% | 4.47% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6558 | 47Neutral | TWD 1.81B | -16.02 | ― | 1.55% | -10.07% | -349.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4111 | Chi Sheng Pharma & Biotech Co., Ltd. | 28.50 | -0.44 | -1.53% | |
| TW:1294 | Hantech Bio-Technology Co., Ltd. | 44.55 | -13.99 | -23.89% | |
| TW:4153 | Diva Laboratories, Ltd. | 31.30 | -0.74 | -2.30% | |
| TW:6558 | SYNergy ScienTech Corp. | 19.40 | -19.85 | -50.57% | |
| TW:6659 | Timing Pharmaceutical Co. Ltd. | 20.35 | -19.61 | -49.07% | |
| TW:6917 | Andros Pharmaceuticals Co., Ltd. | 29.65 | 8.75 | 41.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026